FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2129013602> ?p ?o ?g. }

• W2129013602 endingPage "233" @default.
• W2129013602 startingPage "232" @default.
• W2129013602 abstract "One of the central issues in the treatment of patients with diabetes is whether tight glycemic control will reduce Cardiovascular Disease (CVD) morbidity and mortality. The Diabetes control and complications trial (DCCT) conclusively showed that the greater the average blood glucose in patients with type 1 diabetes, the greater the risk of developing neuropathy, retinopathy and nephropathy. 1 The Diabetes control and complications trialEpidemiology of Diabetes Interventions Complications (DCCTEDIC) trial showed that a history of tight glycemic control significantly reduces the rate of CVD. 2 Data from the Stockholm diabetes intervention study indicated that, in patients with type 1 diabetes, tight control retards the development of atherosclerosis as measured by the development of carotid intima – media thickening. 3 In the United Kingdom Prospective Diabetes Study (UKPDS), a comparison between an intensive treatment group and a conventional treatment group demonstrated a 16% reduction in the risk of fatal and non fatal MI (p=0.052), but all cause mortality did not differ between the two groups. 4 The 10 years follow up of the UKPDS trial showed a reduction of 15% in myocardial events and 13% of death from any cause. 5 While The Action in Diabetes and Vascular Disease: Preterax and Diamicron Modified Release Controlled Evaluation (ADVANCE) study concluded that lowered HbA1c value to 6.5% yielded a 10% relative reduction in the combined outcome of major macrovascular and microvascular events primarily as a consequence of a 21% relative reduction in nephropathy. 6 The study also showed no significant effects of the type of glucose control on major macrovascular events (p=0.32), death from cardiovascular causes (p=0.12) or death from any cause (p =0.28). In the Action to Control Cardiovascular Risk in Diabetes (ACCORD) study, the mean baseline for HbA1c in the intensive therapy group was 8.3+ 1.1%, while it was 8.3+1.1% in the standard group therapy. 7 During the follow up period, (mean of 5.6 years) the study asked whether a therapeutic strategy targeting normal HbA1c of 6.5% would reduce the rate of cardiovascular events with strategy targeting HbA1c on the range of 7-7.9% in the middle aged and older patients with type 2 diabetes. The investigators in the study concluded that intensive therapeutic" @default.
• W2129013602 created "2016-06-24" @default.
• W2129013602 creator A5059903252 @default.
• W2129013602 date "2010-07-01" @default.
• W2129013602 modified "2023-09-23" @default.
• W2129013602 title "Glycemic Control in Diabetes" @default.
• W2129013602 cites W1526927233 @default.
• W2129013602 cites W1752045965 @default.
• W2129013602 cites W2003432843 @default.
• W2129013602 cites W2020591896 @default.
• W2129013602 cites W2139634859 @default.
• W2129013602 cites W2158666727 @default.
• W2129013602 cites W2171294019 @default.
• W2129013602 cites W2337454357 @default.
• W2129013602 cites W2769264260 @default.
• W2129013602 cites W3001949083 @default.
• W2129013602 doi "https://doi.org/10.5001/omj.2010.65" @default.
• W2129013602 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/3191631" @default.
• W2129013602 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/22043346" @default.
• W2129013602 hasPublicationYear "2010" @default.
• W2129013602 type Work @default.
• W2129013602 sameAs 2129013602 @default.
• W2129013602 citedByCount "5" @default.
• W2129013602 countsByYear W21290136022013 @default.
• W2129013602 countsByYear W21290136022016 @default.
• W2129013602 countsByYear W21290136022020 @default.
• W2129013602 countsByYear W21290136022022 @default.
• W2129013602 crossrefType "journal-article" @default.
• W2129013602 hasAuthorship W2129013602A5059903252 @default.
• W2129013602 hasBestOaLocation W21290136021 @default.
• W2129013602 hasConcept C134018914 @default.
• W2129013602 hasConcept C177713679 @default.
• W2129013602 hasConcept C2780473172 @default.
• W2129013602 hasConcept C555293320 @default.
• W2129013602 hasConcept C71924100 @default.
• W2129013602 hasConceptScore W2129013602C134018914 @default.
• W2129013602 hasConceptScore W2129013602C177713679 @default.
• W2129013602 hasConceptScore W2129013602C2780473172 @default.
• W2129013602 hasConceptScore W2129013602C555293320 @default.
• W2129013602 hasConceptScore W2129013602C71924100 @default.
• W2129013602 hasIssue "03" @default.
• W2129013602 hasLocation W21290136021 @default.
• W2129013602 hasLocation W21290136022 @default.
• W2129013602 hasLocation W21290136023 @default.
• W2129013602 hasLocation W21290136024 @default.
• W2129013602 hasOpenAccess W2129013602 @default.
• W2129013602 hasPrimaryLocation W21290136021 @default.
• W2129013602 hasRelatedWork W1563850031 @default.
• W2129013602 hasRelatedWork W2015670292 @default.
• W2129013602 hasRelatedWork W2110217064 @default.
• W2129013602 hasRelatedWork W2415759662 @default.
• W2129013602 hasRelatedWork W2530789867 @default.
• W2129013602 hasRelatedWork W2762039367 @default.
• W2129013602 hasRelatedWork W3036934084 @default.
• W2129013602 hasRelatedWork W3187999478 @default.
• W2129013602 hasRelatedWork W4243328821 @default.
• W2129013602 hasRelatedWork W4254665112 @default.
• W2129013602 hasVolume "25" @default.
• W2129013602 isParatext "false" @default.
• W2129013602 isRetracted "false" @default.
• W2129013602 magId "2129013602" @default.
• W2129013602 workType "article" @default.